Thomas Lingelbach appointed chief executive of Intercell

pharmafile | May 5, 2011 | Appointment | Research and Development appointment, research and development 

Vienna-based biotech Intercell has appointed Thomas Lingelbach as chief executive with effect from 10 May.

He has more than twenty years of experience in the pharma and vaccines industry, and worked at Hoechst AG, Chiron Vaccines, and Novartis Vaccines and Diagnostics before joining Intercell in 2006 as chief operating officer.

Intercell said current its chief executive Gerd Zettlmeissl will resign to pursue other personal and professional interests.

Advertisement

Michel Greco, chairperson of the supervisory board, said: “The supervisory board appreciates very much that Thomas Lingelbach will take over the CEO position. His impressive experience in the industry and at Intercell uniquely qualifies him for his new role to adapt the strategy for the company’s future.

“We want to express our sincere thanks to Gerd Zettlmeissl for his leadership, vision and many years of hard work to grow Intercell into a leader in vaccine biotechnology and wish him all the best for his future.”

Intercell has also elected two new members to its supervisory board – its founder and former chief executive Alexander von Gabain and Thomas Szucs, chairman of BB Biotech and also of the largest Swiss health insurer Helsana.

Meanwhile, David Ebsworth will step down from the board due to the demands on his time required by his recently increased executive responsibilities as chief executive of Swiss healthcare company Galenica.

Related Content

PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025

The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …

AAX Biotech announces collaboration for cardiovascular antibody therapy

Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …

Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months

TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the …

The Gateway to Local Adoption Series

Latest content